Does bone marrow involvement affect prognosis in small-cell lung cancer?

Pasini, Felice; Cetto, Gian Luigi; Pelosi, Giuseppe

doi:10.1023/a:1008271610208

Cited by 9 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is difficult to distinguish synchronous primary malignant tumors from metastatic malignant tumors (2). MCLBMI can be misdiagnosed as SCLC involvement, since BM involvement has been frequently reported in SCLC (19)(20)(21). BM immunophenotyping and histopathological analysis can be used for the differential diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive‑stage small cell lung cancer: A case report and literature review

Fan

Liu

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with an advanced stage; it occurs frequently and affects the lymph nodes, spleen, blood and bone marrow. The synchronous occurrence of MCL bone marrow involvement (MCLBMI) and malignant tumors is extremely rare. To the best of our knowledge, synchronous extensive-stage small cell lung cancer (ES-SCLC) and MCLBMI have not been previously reported. In the present study, a rare case of ES-SCLC with synchronous MCLBMI is reported in a 59-year-old man. The patient received cisplatin, etoposide, dexamethasone and rituximab chemotherapy for the treatment of both malignancies. The follow-up computed tomography scan disclosed regression of the left upper lobe mass and the routine blood test indicated that the platelet count was gradually increasing to normal levels. Following therapy, the patient achieved a partial response. The experience in this case report indicated that the treatment of synchronous SCLC and MCLBMI requires consideration of the respective patient clinical features, biological behavior and cumulative toxicity of the treatment regimens administered for both malignant tumors. The present study demonstrated that thrombocytopenia was not a chemotherapy contraindication, thus providing a new treatment option for this type of patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive‑stage small cell lung cancer: A case report and literature review

Fan

Liu

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Lung cancer most commonly spreads to the bone, liver, adrenal, and brain [5]. Bone marrow is a common site of spreading with micrometastasis appearance for NSCLC [6][7]. Macrometastases are usually uncommon in lung cancers, except in small cell carcinoma; however, even in that case, severe bleeding is a rare initial presentation and an even more rare cause of death.…”

Section: Discussionmentioning

confidence: 99%

Fatal Thrombocytopenia and Thrombocytopathia: An Unusual Onset of Non-Small Cell Lung Cancer

et al. 2003

View full text Add to dashboard Cite

Background: Although bone marrow is a common site of micrometastases for non-small cell lung cancer (NSCLC), thrombocytopathia and hemorrhagic diathesis are rare causes of death. Case Report: A 57-year-old patient was admitted to the emergency room because of massive nosebleeding and hemoptysis. Routine blood analysis showed thrombocytopenia and prolonged bleeding time; results of functional platelet tests suggested concomitant thrombocytopathia. Routine chest X-ray revealed an 18 mm large spot in the right superior lobe. During the first hour of recovery the patient had another episode of nosebleeding. A bone marrow biopsy showed a wide infiltration with neoplastic cells. Histology was compatible with NSCLC. The clinical conditions and hematological parameters progressively deteriorated, and on the third day the patient died because of hypovolemic shock. Conclusion: This is a very rare clinical presentation of NSCLC characterized by massive bleeding due to thrombocytopenia and thrombocytopathia secondary to wide bone marrow infiltration.

show abstract

“…Of the patients potentially suitable at the start of treatment, 68% received thoracic radiotherapy (243 of 354) and 64% PCI (215 of 336)1 -4,6,8-10,14,16,17,19,22,24-28,30. Thoracic radiotherapy was given at a median dose of 50 Gy (range, [40][41][42][43][44][45][46][47][48][49][50][51][52][53][54] and the dose of PCI was 30 Gy, except for British groups who used lower doses (20 and 24 Gy)I-4,14.…”

Section: Radiotherapymentioning

confidence: 99%

High-dose Chemotherapy in Small Cell Lung Cancer

Pasini

Pelosi

Manzoni

et al. 2002

Tumori

View full text Add to dashboard Cite

Improvements in small cell lung cancer (SCLC) therapy with conventional doses of drugs with or without radiotherapy have been poor, and the 5-year survival is discouraging. Since SCLC is highly sensitive to radiotherapy and chemotherapy, some studies have tried to improve survival by increasing the dose of the drugs. Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors (G/GM-CSF) and/or shortening treatment intervals (e.g. weekly regimens). However, dose intensity could be increased by only 20-30% and a survival advantage was not definitively obtained. Given its high chemosensitivity already two decades ago, SCLC was one of the first malignancies deemed suitable for maximizing dose and dose intensity with the support of autologous bone marrow transplantation (ABMT). On the whole, results were disappointing and the procedure was nearly abandoned. Nowadays, some interest is emerging again due to the improvements in supportive care such as the availability of hematopoietic growth factors and the peripheral blood progenitor cells (PBPC).

show abstract

Does bone marrow involvement affect prognosis in small-cell lung cancer?

Cited by 9 publications

References 39 publications

Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive‑stage small cell lung cancer: A case report and literature review

Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive‑stage small cell lung cancer: A case report and literature review

Fatal Thrombocytopenia and Thrombocytopathia: An Unusual Onset of Non-Small Cell Lung Cancer

High-dose Chemotherapy in Small Cell Lung Cancer

Contact Info

Product

Resources

About